Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BPI-9016M is a novel, orally active small molecule tyrosine kinase inhibitor that selectively targets both c-MET and AXL receptor tyrosine kinases. By binding to these targets, BPI-9016M disrupts c-MET and AXL-mediated signaling pathways, leading to inhibition of tumor cell growth, migration, and invasion in cancers with overexpression or dysregulation of these kinases. It is being developed by Betta Pharmaceuticals for advanced non-small cell lung cancer (NSCLC), particularly in patients with c-MET overexpression or MET exon 14 skipping mutations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on BPI-9016M.